Meticulous Research®, a leading global market research company, has recently published an insightful report titled, "Psoriasis Treatment Market Size, Share, Forecast, & Trends Analysis by Treatment (TNF Inhibitor, Interleukin, Corticosteroids, Calcitrol, Retinoids, Calcineurin, Methotrexate) Disease (Plaque Psoriasis, Psoriatic Arthritis) – Global Forecast to 2031."
Request pdf @ https://www.meticulousresearch.com/download-sample-report/cp_id=5908
According to this latest publication, the global psoriasis treatment market is projected to reach $35.07 billion by 2031, growing at a compound annual growth rate (CAGR) of 9.8% from 2024 to 2031. The market's growth is driven by several key factors:
- High Burden of Psoriasis: The significant prevalence of psoriasis worldwide necessitates effective treatment solutions.
- Advancements in Treatment Options: Continuous innovations in psoriasis treatment are enhancing patient outcomes.
- Improved Diagnosis: Better diagnostic techniques are aiding early detection and treatment of psoriasis.
- Understanding of Disease Pathogenesis: Advances in understanding the mechanisms behind psoriasis are leading to more targeted therapies.
- Aging Population: An increasing number of elderly individuals, who are more susceptible to psoriasis, is boosting market demand.
Opportunities and Trends
- Rising Awareness: Growing awareness about psoriasis and its treatments is expanding the market.
- Combination Therapies: The increasing use of combination therapies for more effective treatment is driving market growth.
- Research and Development: Ongoing research into psoriasis is creating new opportunities for market players.
Key Players
The report highlights several major players in the psoriasis treatment market, including:
- AbbVie Inc. (U.S.)
- AstraZeneca Plc (U.K.)
- Boehringer Ingelheim (Germany)
- Celgene Corporation (U.S.)
- Eli Lilly and Company (U.S.)
Market Segmentation
The psoriasis treatment market is segmented based on treatment type, disease type, route of administration, distribution channel, and geography.
By Treatment Type
- Biologic Drugs:
- TNF Inhibitors: Infliximab, Adalimumab, Etanercept, and others.
- Interleukin Inhibitors: Guselkumab, Risankizumab, Tildrakizumab, and others.
- Others
- Topical Treatments:
- Corticosteroids: Hydrocortisone, Desonide, Betamethasone, and others.
- Vitamin D Analogs: Calcitrol, Calcipotriol, Tacalcitol.
- Retinoids
- Calcineurin Inhibitors
- Systemic Treatments:
- Methotrexate
- Cyclosporine
- Acitretin
- Others
The biologic drugs segment is projected to witness the highest growth rate during the forecast period. This growth is driven by the increasing adoption of interleukin inhibitors due to their high efficacy and favorable safety profiles, advancements in biologic drug development, and initiatives by companies to launch new biologics for psoriasis.
By Disease Type
- Plaque Psoriasis
- Psoriatic Arthritis
- Others
By Route of Administration
- Oral
- Topical
- Injectable
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online/E-commerce Platforms
Future Outlook
The global psoriasis treatment market is poised for significant growth, driven by advancements in treatment options, rising awareness about the condition, and ongoing research. As more effective therapies are developed and awareness continues to spread, the market will offer ample opportunities for both established players and new entrants.
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
